Moffitt Cancer Center and Cryoport Partner to Advance Global Innovation at Speros Campus

Moffitt Cancer Center, through its subsidiary Speros FL, and Cryoport, Inc. have announced a strategic collaboration to establish CRYOGENE’s advanced biorepository services on the Speros global innovation life sciences campus in Pasco County, Florida. This partnership marks a significant step toward transforming the Speros campus into a world-class hub for cell and gene therapy innovation, accelerating research and discovery efforts.

"With CRYOGENE’s biostorage facility integrated into our campus, we are building the foundation to make Speros the global epicenter of cell and gene therapy,” said Dr. Patrick Hwu, President and CEO of Moffitt. The facility will enable researchers and biotech companies to collaborate more effectively, fueling the development of cutting-edge therapies. Marshall Griswold, CEO of CRYOGENE, emphasized the shared mission to improve patients' lives, highlighting the strategic alignment between Cryoport’s expertise and Moffitt’s vision. Positioned alongside Moffitt’s Discovery & Innovation Center, this collaboration reinforces Speros’ standing as a leader in advancing therapies and technologies in cancer treatment and beyond.